- History of MDMA and Psilocybin
- Physiological effects and side effects, risk/benefit profile
- Design of past and ongoing non-profit-sponsored clinical trials of MDMA-assisted psychotherapy
- Results of Six Completed MDMA Phase 2 Clinical trials
- Design of ongoing Phase 3 Trials of MDMA-assisted psychotherapy
- Overview of psilocybin clinical trials
- Status of FDA drug development – MDMA and Psilocybin, including Breakthrough Therapy Designation
- The manualized therapeutic method used in clinical trials of MDMA-assisted psychotherapy
- Essential elements of “inner directed” approach
- Illustrated elements of “inner directed” approach
- Challenges that may arise
- Therapist training program for MDMA-assisted psychotherapy
Free Test Alert
You have been selected to receive a free test alert - on us!
The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD
As psychiatry struggles to develop new, more effective treatments, clinical trials combining psychotherapy and the drug MDMA, also known as Ecstasy, are producing stunning results. New research suggests that incorporating psychedelics like MDMA and psilocybin into talk therapy can dramatically boost outcomes with an array of issues, including PTSD, anxiety, depression, relationship blocks, even drug addiction. If ongoing trials continue with favorable results, FDA approval for certified therapists to use MDMA- and psilocybin-assisted therapy in their practices could be on the horizon. Guided in this workshop by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:
- The rationale for using drugs like MDMA, psilocybin and other psychedelics as catalysts for psychotherapy
- The MDMA-assisted psychotherapy process, illustrated with video clips
- How these inner-directed approaches to therapy respect and support clients' innate healing intelligence
- New opportunities for psychotherapists to receive training in this approach
Here's What You'll Learn
Everything You're Getting
- More than 1 hour of video content
- CE information to come
- Handouts and resources
We Recommend
This Item
Meet Your Experts
Michael Mithoefer, MD
Toggle speaker biography
Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.
Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Columbia University, Bassett Healthcare Network, University of South Carolina, Lykos Therapeutics and has ownership interest in Awakn Life Sciences. He is a sub-investigator and therapist at Zen Therapeutics and a consultant with MAPS. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.
100% Demo Guarantee
Register for this intensive training course without risk. If you're not completely satisfied, give us a call at 800-844-8260. We're that confident you'll find this learning experience to be all that's promised and more than you expected.
PESI Mobile App
Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world's best instructors, and complete your CE requirements anywhere, anytime, at your own pace.
Access for Self-Study (Non-Interactive)
Access never expires for this product.
Questions?
Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info
- Media Type:
- Digital Seminar
- Product Code:
- POS052733
- Duration:
- 1 hour, 30 minutes
- Copyright:
- May 28, 2021
- Closed Captions:
- Available
- Format:
- Audio and Video
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.